Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25326413 | 0.86 | CHRNB2 (0.41) | MGLLP2RX3P2RX2LIPE | |
| SCHEMBL20249283 | 0.82 | SLC6A2 (0.44) | — | |
| SCHEMBL15221721 | 0.79 | LIPE (0.40) | CSF1RFLT3PDGFRBPDGFRALIPE | |
| SCHEMBL27246537 | 0.79 | LIPE (0.40) | MGLLP2RX3P2RX2LIPE | |
| SCHEMBL20249213 | 0.78 | HRH1 (0.47) | CSF1RFLT3 | |
| SCHEMBL20085932 | 0.76 | PARP10 (0.39) | PDGFRBPDGFRALIPE | |
| SCHEMBL20249208 | 0.76 | CHRNB2 (0.54) | — | |
| SCHEMBL22583402 | 0.76 | CHEK1 (0.34) | MGLLP2RX3P2RX2 | |
| SCHEMBL20249288 | 0.76 | CHRNB2 (0.54) | — | |
| SCHEMBL20249289 | 0.76 | CHRNB2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | CSF1R 3622/4885FLT3 289/4885MGLL 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.